Literature DB >> 31449805

Hypnotherapy or medications: a randomized noninferiority trial in urgency urinary incontinent women.

Yuko M Komesu1, Ronald M Schrader2, Rebecca G Rogers3, Robert E Sapien4, Andrew R Mayer5, Loren H Ketai4.   

Abstract

BACKGROUND: Urgency urinary incontinence afflicts many adults, and most commonly affects women. Medications, a standard treatment, may be poorly tolerated, with poor adherence. This warrants investigation of alternative interventions. Mind-body therapies such as hypnotherapy may offer additional treatment options for individuals with urgency urinary incontinence.
OBJECTIVE: To evaluate hypnotherapy's efficacy compared to medications in treating women with urgency urinary incontinence.
MATERIALS AND METHODS: This investigator-masked, noninferiority trial compared hypnotherapy to medications at an academic center in the southwestern United States, and randomized women with non-neurogenic urgency urinary incontinence to weekly hypnotherapy sessions for 2 months (and continued self-hypnosis thereafter) or to medication and weekly counseling for 2 months (and medication alone thereafter). The primary outcome was the between-group comparison of percent change in urgency incontinence on a 3-day bladder diary at 2 months. Important secondary outcomes were between-group comparisons of percent change in urgency incontinence at 6 and 12 months. Outcomes were analyzed based on noninferiority margins of 5% for between group differences (P < 0.025) (that is, for between group difference in percentage change in urgency incontinence, if the lower bound of the 95% confidence interval was greater than -5%, noninferiority would be proved).
RESULTS: A total of 152 women were randomized to treatment between April 2013 and October 2016. Of these women, 142 (70 hypnotherapy, 72 medications) had 3-day diary information at 2 months and were included in the primary outcome analysis. Secondary outcomes were analyzed for women with diary data at the 6-month and then 12-month time points (138 women [67 hypnotherapy, 71 medications] at 6 months, 140 women [69 hypnotherapy, 71 medications] at 12 months. There were no differences between groups' urgency incontinence episodes at baseline: median (quartile 1, quartile 3) for hypnotherapy was 8 (4, 14) and medication was 7 (4, 11) (P = .165). For the primary outcome, although both interventions showed improvement, hypnotherapy did not prove noninferior to medication at 2 months. Hypnotherapy's median percent improvement was 73.0% (95% confidence interval, 60.0-88˖9%), whereas medication's improvement was 88.6% (95% confidence interval, 78.6-100.0%). The median difference in percent change between groups was 0% (95% confidence interval, -16.7% to 0.0%); because the lower margin of the confidence interval did not meet the predetermined noninferiority margin of greater than -5%, hypnotherapy did not prove noninferior to medication. In contrast, hypnotherapy was noninferior to medication for the secondary outcomes at 6 months (hypnotherapy, 85.7% improvement, 95% confidence interval, 75.0-100%; medications, 83.3% improvement, 95% confidence interval, 64.7-100%; median difference in percent change between groups of 0%, 95% confidence interval, 0.0-6.7%) and 12 months (hypnotherapy, 85.7% improvement, 95% confidence interval, 66.7-94.4%; medications, 80% improvement, 95% confidence interval, 54.5-100%; median difference in percent change between groups of 0%, 95% confidence interval, -4.2% to -9.5%).
CONCLUSION: Both hypnotherapy and medications were associated with substantially improved urgency urinary incontinence at all follow-up. The study did not prove the noninferiority of hypnotherapy compared to medications at 2 months, the study's primary outcome. Hypnotherapy proved noninferior to medications at longer-term follow-up of 6 and 12 months. Hypnotherapy is a promising, alternative treatment for women with UUI.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  hypnotherapy; mind-body therapy; pharmacotherapy; randomized trial in women; urgency urinary incontinence

Mesh:

Substances:

Year:  2019        PMID: 31449805      PMCID: PMC6995419          DOI: 10.1016/j.ajog.2019.08.025

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  35 in total

1.  Brain control of normal and overactive bladder.

Authors:  Derek Griffiths; Stuart Derbyshire; Andy Stenger; Neil Resnick
Journal:  J Urol       Date:  2005-11       Impact factor: 7.450

Review 2.  Brain correlates of hypnosis: A systematic review and meta-analytic exploration.

Authors:  Mathieu Landry; Michael Lifshitz; Amir Raz
Journal:  Neurosci Biobehav Rev       Date:  2017-02-24       Impact factor: 8.989

3.  Brain Activity and Functional Connectivity Associated with Hypnosis.

Authors:  Heidi Jiang; Matthew P White; Michael D Greicius; Lynn C Waelde; David Spiegel
Journal:  Cereb Cortex       Date:  2017-08-01       Impact factor: 5.357

Review 4.  Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment.

Authors:  E Ann Gormley; Deborah J Lightner; Martha Faraday; Sandip Prasan Vasavada
Journal:  J Urol       Date:  2015-01-23       Impact factor: 7.450

5.  Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial.

Authors:  Carla E Flik; Wijnand Laan; Nicolaas P A Zuithoff; Yanda R van Rood; André J P M Smout; Bas L A M Weusten; Peter J Whorwell; Niek J de Wit
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-11-23

6.  Increased attentional network functioning related to symptom severity measures in females with irritable bowel syndrome.

Authors:  C S Hubbard; J Hong; Z Jiang; B Ebrat; B Suyenobu; S Smith; N Heendeniya; B D Naliboff; K Tillisch; E A Mayer; J S Labus
Journal:  Neurogastroenterol Motil       Date:  2015-06-19       Impact factor: 3.598

7.  Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.

Authors:  Ananias C Diokno; Rodney A Appell; Peter K Sand; Roger R Dmochowski; Bernard M Gburek; Ira W Klimberg; Sherron H Kell
Journal:  Mayo Clin Proc       Date:  2003-06       Impact factor: 7.616

8.  Impact of overactive bladder on work productivity in the United States: results from EpiLUTS.

Authors:  Chris C Sexton; Karin S Coyne; Vasudha Vats; Zoe S Kopp; Debra E Irwin; Todd H Wagner
Journal:  Am J Manag Care       Date:  2009-03       Impact factor: 2.229

9.  Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.

Authors:  Anna O D'Souza; Michael J Smith; Lesley-Ann Miller; Joseph Doyle; Rinat Ariely
Journal:  J Manag Care Pharm       Date:  2008-04

10.  Multiple Chronic Conditions and Use of Complementary and Alternative Medicine Among US Adults: Results From the 2012 National Health Interview Survey.

Authors:  Laura Falci; Zaixing Shi; Heather Greenlee
Journal:  Prev Chronic Dis       Date:  2016-05-05       Impact factor: 2.830

View more
  1 in total

1.  Identification and characterization of novel endolysins targeting Gardnerella vaginalis biofilms to treat bacterial vaginosis.

Authors:  Sara Arroyo-Moreno; Matthew Cummings; David B Corcoran; Aidan Coffey; Ronan R McCarthy
Journal:  NPJ Biofilms Microbiomes       Date:  2022-04-19       Impact factor: 8.462

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.